<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752243</url>
  </required_header>
  <id_info>
    <org_study_id>FFM-CIK-Cell Study 01</org_study_id>
    <secondary_id>2013-005446-11</secondary_id>
    <nct_id>NCT02752243</nct_id>
  </id_info>
  <brief_title>CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.</brief_title>
  <official_title>A Prospective Phase I/II Study to Investigate the Feasibility, Safety and Efficacy of IL-15 Activated Cytokine Induced Killer (CIK) Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After Allogeneic SCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Bader</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-site, non-randomized Phase I/II study involving children and adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II multicenter-study to investigate the feasibility safety and efficacy of&#xD;
      interleukin (IL)-15 activated CIK cells in patients with acute leukemia or myelodysplastic&#xD;
      syndrome (MDS) showing evidence of relapse after allogeneic stem cell transplantation (SCT).&#xD;
&#xD;
      CIK cell infusions will be given with an interval of 4-6 weeks according to a dose escalation&#xD;
      schedule in patients with impending relapse after allogeneic SCT. In presence of acute graft&#xD;
      versus host disease (aGvHD) ≥ grade II, the next scheduled infusion will not be administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of grade three or four acute Graft versus Host Disease (aGvHD)</measure>
    <time_frame>two until four weeks after CIK-Cell Infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Extensive chronic Graft versus Host Disease (cGvHD)</measure>
    <time_frame>two until four weeks after CIK-Cell Infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of CIK-Cells analyzed by progression free survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>CIK-Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIK-Cells</intervention_name>
    <description>IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.</description>
    <arm_group_label>CIK-Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Acute leukemia and MDS patients with molecular or cytogenetic relapse in peripheral blood&#xD;
        (PB) or bone marrow (BM) samples obtained during monitoring for relapse after allogeneic&#xD;
        SCT.&#xD;
&#xD;
        MRD detected by Ig/TCR gene rearrangement testing or any detected disease specific DNA or&#xD;
        RNA sequence or disease specific cell surface Proteins or mixed recipient chimerism (MC) ≥&#xD;
        1% and &lt; 40%, or levels ≥ 10-4 of BCR-ABL/ABL ratio or any other disease specific&#xD;
        cytogenetic abnormality will trigger CIK cell interventions.&#xD;
&#xD;
          -  Respecting MC, MC = 1% of autologous/recipient signals in PB samples must be confirmed&#xD;
             by another PB or BM sample within one week. Patients with MC = 1% of&#xD;
             autologous/recipient signals in CD33+ and/or CD34+ subpopulations in PB samples must&#xD;
             be confirmed by BM analyses within one week. Acute leukemia and MDS patients with MC =&#xD;
             1% of autologous/recipient signals including signals in CD33+ and/or CD34+&#xD;
             subpopulations in BM samples must not be confirmed.&#xD;
&#xD;
          -  Acute leukemia and MDS patients with frank relapse ≥ 120 days after allogeneic SCT who&#xD;
             achieved complete remission (CR) or blast clearance (i.e. &lt;5% blasts) in the bone&#xD;
             marrow after re-induction chemotherapy.&#xD;
&#xD;
          -  All patients must be in complete remission or have achieved blast clearance (i.e. &lt;5%&#xD;
             blasts) in the bone marrow before 1st CIK cell treatment (bone marrow assessment at a&#xD;
             maximum of 7 days in advance of 1st treatment is obligatory).&#xD;
&#xD;
          -  Patients without immunosuppressive agents and steroids for at least 7 days.&#xD;
&#xD;
          -  Patients without chemo- or immune therapy during CIK cell treatment, except patients&#xD;
             with thyrosine-kinase inhibitors (TKI) for treatment of BCR-ABL positive leukemia.&#xD;
             Last DLI treatment must be 4 weeks before 1st CIK cell treatment.&#xD;
&#xD;
          -  Patients with &lt; grade II aGvHD.&#xD;
&#xD;
          -  Patients with Karnowsky or Lansky performance status ≥ 50%.&#xD;
&#xD;
          -  Patients and/or his/her legal representative having reviewed the patient&#xD;
             information/informed consent form and have had their questions answered and have given&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute leukemia and MDS patients with hematologic relapse &lt; day 120 after allogeneic&#xD;
             stem cell transplantation.&#xD;
&#xD;
          -  Patients with 5% and more malignant cells in a representative bone marrow analysis&#xD;
             performed at a maximum of 7 days before 1st CIK cell treatment (obligatory).&#xD;
&#xD;
          -  Patients with immunosuppressive agents or steroids.&#xD;
&#xD;
          -  Patients with chemo- or immune therapy, except patients with thyrosine-kinase&#xD;
             inhibitors (TKI) for BCR-ABL positive leukemias.&#xD;
&#xD;
          -  Patients with ≥ grade II GvHD.&#xD;
&#xD;
          -  Patients with rapid T cell regeneration and any signs of GvHD&#xD;
&#xD;
          -  Patients with Karnowsky or Lansky performance status &lt; 50%.&#xD;
&#xD;
          -  Patients and/or his/her legal representative having reviewed the patient&#xD;
             information/informed consent form and have had their questions answered and have not&#xD;
             given written informed consent.&#xD;
&#xD;
          -  HIV-positive patients.&#xD;
&#xD;
          -  HBV/HCV positive patients.&#xD;
&#xD;
          -  Patients with prior solid organ transplantation.&#xD;
&#xD;
          -  Patients treated with any other investigational product within the last 28 days or&#xD;
             five half-lives (whichever is longer).&#xD;
&#xD;
          -  Hypersensitivity to any component of the study drug&#xD;
&#xD;
          -  Female patients of child-bearing potential not agreeing to use a highly effective&#xD;
             method of birth control resulting in a low failure rate (i.e. &lt; 1%) when used&#xD;
             consistently and correctly.&#xD;
&#xD;
          -  Male patients with female partners of childbearing potential not agreeing to use a&#xD;
             highly effective method birth control resulting in a low failure rate (i.e. &lt; 1%) when&#xD;
             used consistently and correctly.&#xD;
&#xD;
          -  Pregnancy/Breastfeeding.&#xD;
&#xD;
          -  Patients with severe infections or signs/symptoms of infection within 2 weeks prior to&#xD;
             study start.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Heidelberg, Ruprecht Karls University, Hospital for children and adolescents, Pediatrics III, Department of Oncology, Haematology, Immunology and Pneumology</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt / Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine II, Department of Hematology, Oncology, Rheumatology and Infectious Diseases, Goethe-University Frankfurt/Main</name>
      <address>
        <city>Frankfurt / Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medicine Duesseldorf, Department of Paediatric Oncology, Haematology and Immunology, Bone Marrow Transplantation Unit</name>
      <address>
        <city>Duesseldorf</city>
        <state>North Rhine-Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine III, Department of Hematology and Oncology, Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland Palatinate</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Bader</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>acute leukemia</keyword>
  <keyword>myelodysplastic syndrome (MDS)</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

